Kyverna Therapeutics, Inc. KYTX Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -64.7%— | —— | |
| Return on assets | -53.9%+13.2pp | -67.1%— | |
| Return on invested capital | -116.4%— | —— | |
| Liquidity | |||
| Current ratio | 7.8×-0.9× | 8.6×+5.6× | |
| Quick ratio | 7.8×-0.9× | 8.6×+5.6× | |
| Cash ratio | 3.4×+0.5× | 2.9×+1.1× | |
| Leverage | |||
| Debt-to-equity | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×-0.1× | |
| Interest coverage | -346.6×+658× | -1,004.3×-671× | |
| Per Share | |||
| Book value per share | $5.25-24.5% | $6.95+136% | |
| Valuation | |||
| Market capitalization | $498.52M+276% | $161.46M— | |
| Enterprise value | $475.49M+475% | $73.86M— | |
| Price / book | 2.5×+2.0× | 0.6×— | |
| Free cash flow yield | -27.4%+44.7pp | -72.1%— | |
| Earnings yield | -31.4%+78.2pp | -79%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kyverna Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Kyverna Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.